**Alibaba to Pay $600 Million to Settle Allegations of Illegal Drug Sales in the U.S.**
**Published: July 2, 2026**
Chinese e-commerce giant Alibaba, along with its U.S.-based payment processor AUS Merchant Services, has agreed to pay $600 million to settle allegations regarding their failure to prevent the sale of illegal drugs on their platforms. This settlement comes as part of an investigation led by the U.S. Department of Justice (DOJ), which found that the companies violated the Federal Food, Drug, and Cosmetic Act.
The DOJ announced the settlement on Wednesday, highlighting that both Alibaba and AUS Merchant Services have accepted responsibility for the actions of their employees and officers. As part of the agreement, the companies will also enhance their compliance programs to better prevent the sale of illegal products in the future.
According to the DOJ, the investigation revealed that between 2016 and 2024, Alibaba failed to prevent approximately 80,000 sales of illegal drugs, chemicals, and pharmaceutical counterfeiting equipment. These transactions were valued at over $200 million. The investigation included more than 40 undercover purchases made by law enforcement, which confirmed the sale of illegal pharmaceuticals and related equipment through Alibaba's platforms.
During the investigation, it was noted that some Alibaba employees expressed concerns regarding the adequacy of the company's compliance measures in preventing the sale of illegal products. This raised questions about the effectiveness of the company's policies in safeguarding against such transactions.
Assistant U.S. Attorney General Brett Shumate emphasized the importance of the settlement, stating, "Today’s resolution reflects the Department of Justice’s commitment to ensuring that companies operating e-commerce and digital payment platforms keep illegal, unapproved, misbranded, and dangerous foreign pharmaceuticals off their marketplaces."
In response to the allegations, Alibaba stated that the settlement reflects a thorough regulatory process and demonstrated the company's commitment to maintaining high standards of control and compliance against non-compliant product sales. The company has indicated that it will work to strengthen its compliance programs to prevent future violations.
Alibaba operates several of the world's largest e-commerce platforms, including Alibaba.com and AliExpress.com, which serve millions of users globally. The settlement marks a significant moment for the company as it navigates regulatory scrutiny in various markets, particularly in the United States.
This case highlights ongoing concerns regarding the sale of illegal and potentially harmful products through online platforms, raising questions about the responsibilities of e-commerce companies in monitoring and regulating the activities of their merchants. As the digital marketplace continues to grow, the implications of this settlement may influence how similar companies approach compliance and oversight in the future.